JP2022517189A5 - - Google Patents

Info

Publication number
JP2022517189A5
JP2022517189A5 JP2021539020A JP2021539020A JP2022517189A5 JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5 JP 2021539020 A JP2021539020 A JP 2021539020A JP 2021539020 A JP2021539020 A JP 2021539020A JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5
Authority
JP
Japan
Prior art keywords
amino
oxo
isopropyl
pyrimidine
dihydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517189A (ja
JP7539892B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012058 external-priority patent/WO2020142612A1/en
Publication of JP2022517189A publication Critical patent/JP2022517189A/ja
Publication of JP2022517189A5 publication Critical patent/JP2022517189A5/ja
Application granted granted Critical
Publication of JP7539892B2 publication Critical patent/JP7539892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539020A 2019-01-03 2020-01-02 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物 Active JP7539892B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/070275 2019-01-03
CN2019070275 2019-01-03
CN2019081673 2019-04-08
CNPCT/CN2019/081673 2019-04-08
PCT/US2020/012058 WO2020142612A1 (en) 2019-01-03 2020-01-02 Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.

Publications (3)

Publication Number Publication Date
JP2022517189A JP2022517189A (ja) 2022-03-07
JP2022517189A5 true JP2022517189A5 (cg-RX-API-DMAC7.html) 2023-01-04
JP7539892B2 JP7539892B2 (ja) 2024-08-26

Family

ID=69400641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539020A Active JP7539892B2 (ja) 2019-01-03 2020-01-02 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物

Country Status (6)

Country Link
US (1) US12344603B2 (cg-RX-API-DMAC7.html)
EP (1) EP3941919B1 (cg-RX-API-DMAC7.html)
JP (1) JP7539892B2 (cg-RX-API-DMAC7.html)
CN (1) CN113508115A (cg-RX-API-DMAC7.html)
TW (1) TWI748317B (cg-RX-API-DMAC7.html)
WO (1) WO2020142612A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI756636B (zh) * 2019-02-18 2022-03-01 美商建南德克公司 嘧啶并嘧啶化合物及使用方法
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
CN118561841A (zh) * 2020-12-18 2024-08-30 豪夫迈·罗氏有限公司 新的芳基-吡啶并-嘧啶-酮衍生物
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
CN115850281A (zh) * 2021-09-24 2023-03-28 华东理工大学 蝶啶酮衍生物及其应用
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
CN119343346A (zh) * 2022-06-08 2025-01-21 韩国化学研究院 苯磺酰胺衍生物、其制备方法及含有其作为活性成分的预防或治疗癌症的药物组合物
WO2024131893A1 (en) * 2022-12-22 2024-06-27 Shanghai Yi Zhong Xing Biotechnology Co., Ltd. IRE1α SMALL MOLECULE INHIBITORS
US12573866B2 (en) 2023-11-17 2026-03-10 Exro Technologies Inc. Battery system for operating point control of power systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP2003509425A (ja) * 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
KR100571339B1 (ko) * 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
WO2004063195A1 (en) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2005034869A2 (en) * 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2006002367A1 (en) * 2004-06-23 2006-01-05 Irm Llc Compounds and compositions as protein kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
WO2006082492A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
JP2009537520A (ja) * 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Fgf受容体キナーゼ阻害剤のための組成物および方法
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008055842A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
WO2011097526A1 (en) * 2010-02-05 2011-08-11 Irm Llc Compounds and compositions as protein kinase inhibitors
BR112014010631A2 (pt) * 2011-11-04 2017-04-25 Afraxis Holdings Inc inibidores de pak para o tratamento da síndrome do x frágil
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2014179498A1 (en) * 2013-04-30 2014-11-06 Genentech, Inc. Serine/threonine kinase inhibitors
US20140323478A1 (en) * 2013-04-30 2014-10-30 Afraxis Holdings, Inc. Serine/threonine kinase inhibitors
WO2014182829A1 (en) * 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
TW201838981A (zh) 2017-03-17 2018-11-01 美商建南德克公司 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
AU2018278311B2 (en) 2017-06-01 2021-10-07 Cornell University IRE1 small molecule inhibitors
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
JP7546299B2 (ja) 2018-12-03 2024-09-06 コーネル・ユニバーシティー Ire1小分子阻害物質
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
KR102396930B1 (ko) 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물

Similar Documents

Publication Publication Date Title
JP6754864B2 (ja) Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2026009899A (ja) NaV1.8を阻害するピリジンカルボキサミド化合物
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
JP2021524484A5 (cg-RX-API-DMAC7.html)
KR20260047565A (ko) 통증에 대한 신규 치료
JP7539892B2 (ja) 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物
KR20010050223A (ko) Crf 길항제 및 관련 조성물의 용도
ES2798424T3 (es) Compuestos de triazolopiridina y usos de estos
JP7611154B2 (ja) ピリド-ピリミジニル化合物及び使用の方法
JP7320600B2 (ja) フェノキシ-ピリジル-ピリミジン化合物及び使用方法
JP2005538099A5 (cg-RX-API-DMAC7.html)
JP2011510995A5 (cg-RX-API-DMAC7.html)
JP2013056930A5 (cg-RX-API-DMAC7.html)
RU2009125916A (ru) Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
JP7768880B2 (ja) Ezh2を阻害するためのキノリン化合物および組成物
US20240245634A1 (en) Pcna inhibitors and egfr inhibitors for cancer treatment
JP2022539830A5 (cg-RX-API-DMAC7.html)
JP2022550353A (ja) アザキノリン化合物およびその使用
KR20170129757A (ko) Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
WO2020176501A1 (en) Compounds useful for inhibiting raf dimers
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
RU2393157C1 (ru) 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
HK40097521A (en) Tricyclic compounds and uses thereof
HK40080941A (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases